All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Real-World and Post-Hoc Analyses Support Luspatercept Use in Low-Risk Myelodysplastic Syndrome

July 17th 2024

Guillermo Garcia-Manero, MD, spotlights 3 key analyses of luspatercept in low-risk myelodysplastic syndrome presented at the 2024 EHA Congress.

Darolutamide Plus ADT Provides Statistically Significant rPFS Advantage in mHSPC

July 17th 2024

Darolutamide plus ADT improved radiologic PFS vs placebo plus ADT in men with metastatic hormone-sensitive prostate cancer enrolled in the phase 3 ARANOTE trial.

U.S. News & World Report Once Again Ranks Hackensack University Medical Center the 1 Hospital in New Jersey

July 17th 2024

U.S. News & World Report named Hackensack Meridian Hackensack University Medical Center the #1 hospital in New Jersey on its annual Best Hospitals list.

NCCN Updates Kidney Cancer Clinical Practice Guidelines

July 17th 2024

The National Comprehensive Cancer Network has published their updated Clinical Practice Guidelines in Oncology for kidney cancer.

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

July 17th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

INCB057643 ± Ruxolitinib Shows Early Tolerability, Efficacy in Advanced Myelofibrosis

July 16th 2024

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

TQB2930 is Well Tolerated, Elicits Antitumor Activity in HER2+ Advanced Breast Cancer

July 16th 2024

TQB2930 was well tolerated and generated responses in HER2-positive advanced breast cancer.

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

July 16th 2024

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

Fox Chase Researchers Present Data on Integrating Palliative Care Education Into Hematology-Oncology Fellowships

July 16th 2024

Jessica Bauman, MD, found that a new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge.

Oral Bexarotene Gains Marketing Authorization for CTCL in Hong Kong

July 16th 2024

Bexarotene has been granted marketing authorization in Hong Kong for the treatment of pretreated cutaneous manifestations of cutaneous T-cell lymphoma.

FDA Grants Fast Track Designation to ABD-147 for ES-SCLC

July 16th 2024

The FDA has awarded fast track designation to the next-generation precision radiopharmaceutical therapy ABD-147 for the treatment of patients with ES-SCLC.

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

July 16th 2024

Adjuvant nivolumab plus ipilimumab significantly improved 3-year DMFS rates compared with historical controls in patients with high-risk uveal melanoma.

RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC

July 16th 2024

RMC-6236 led to early antitumor activity with an acceptable safety profile in patients with previously treated pancreatic ductal adenocarcinoma.

FDA Places Partial Clinical Hold on Phase 1 Trial of Seclidemstat Plus Azacitidine in MDS/CMML

July 16th 2024

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies

July 15th 2024

The addition of ipilimumab to cabozantinib plus nivolumab was safe and showed notable efficacy in patients with rare genitourinary cancers.

Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials

July 15th 2024

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions

July 15th 2024

IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions.

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

July 15th 2024

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML

July 15th 2024

The investigational menin-MLL inhibitor DSP-5336 has received FDA fast track designation in KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

FDA Completes End-of-Phase 2 Meeting for Annamycin Plus Cytarabine in AML

July 15th 2024

Moleculin Biotech completed an end-of-phase 2 meeting with the FDA regarding the investigation of annamycin plus cytarabine in acute myeloid leukemia.